On the Inclusion of Non‐Concurrent Controls in Platform Trials With an Interim Analysis
Open Access
- 18 May 2026
- journal article
- Published by Wiley in Statistics in Medicine
- Vol. 45 (10-12) , e70585
Abstract
The analysis of platform trials can be enhanced by utilizing non‐concurrent controls. Since including this data might also introduce bias in the treatment effect estimators if time trends are present, methods for incorporating non‐concurrent controls adjusting for time have been proposed. However, so far their behavior has not been systematically investigated in platform trials that include interim analyses. To evaluate the impact of an interim analysis in trials utilizing non‐concurrent controls, we consider a platform trial featuring two experimental arms and a shared control, with the second experimental arm entering later. We focus on a frequentist regression model that uses non‐concurrent controls to estimate the treatment effect of the second arm and adjusts for time using a step function to account for temporal changes. We show that performing an interim analysis in Arm 1 may introduce bias in the point estimation of the effect in Arm 2, if the regression model is used without adjustment, and investigate how the marginal bias and bias conditional on the first arm continuing after the interim depend on different trial design parameters. Moreover, we propose a new estimator of the treatment effect in Arm 2, aiming to eliminate the bias introduced by both the interim analysis in Arm 1 and the time trends, and evaluate its performance in a simulation study. The newly proposed estimator is shown to substantially reduce the bias and type I error rate inflation while leading to power gains compared to an analysis using only concurrent controls.Keywords
All Related Versions
Funding Information
- Agència de Gestió d'Ajuts Universitaris i de Recerca (2024 FI‐1 00401)
- Ministerio de Ciencia, Innovación y Universidades (PID2023‐148033OB‐C21)
- Departament d'Empresa i Coneixement, Generalitat de Catalunya (2021 SGR 01421)
- Innovative Health Initiative (101165912)
This publication has 33 references indexed in Scilit:
- Collaborative Platform Trials to Fight COVID‐19: Methodological and Regulatory Considerations for a Better Societal OutcomeClinical Pharmacology & Therapeutics, 2021
- The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature ReviewClinical Therapeutics, 2020
- Including non-concurrent control patients in the analysis of platform trials: is it worth it?BMC Medical Research Methodology, 2020
- Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform TrialsClinical Pharmacology & Therapeutics, 2020
- Adaptive platform trials: definition, design, conduct and reporting considerationsNature Reviews Drug Discovery, 2019
- Master Protocols to Study Multiple Therapies, Multiple Diseases, or BothNew England Journal of Medicine, 2017
- Robust meta‐analytic‐predictive priors in clinical trials with historical control informationBiometrics, 2014
- Use of historical control data for assessing treatment effects in clinical trialsPharmaceutical Statistics, 2013
- Conditional Bias of Point Estimates Following a Group Sequential TestJournal of Biopharmaceutical Statistics, 2004
- Confidence Intervals for a Normal Mean Following a Group Sequential TestBiometrics, 1989